GlobeNewswire

Ovum Survey Finds NetSfere Among The Top 3 Most Widely Deployed Secure Enterprise Messaging Services

Dela

NetSfere is the third most used enterprise platform, clearly outpacing legacy enterprise communication vendors

 

CHICAGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- A report by Ovum, a market-leading research and consulting firm, commissioned by Infinite Convergence Solutions, a global leader in messaging and mobility solutions, finds that within just a few short years of launching, NetSfere is ranked as the third most used enterprise messaging service behind Skype Business and Cisco's Spark.

In addition to the need for a secure messaging service, the report shows enterprise demand for communication services that enable collaboration beyond messaging. NetSfere's combined HD voice, video and text capabilities - all preferred means of communication in one encrypted platform - validates its ranking among the top services for enterprises.

"With messaging services advancing into all-in-one communications platforms, there's a greater propensity for widespread business use - but also major security risks," said Anurag Lal, CEO and President of Infinite Convergence Solutions, creators of NetSfere. "NetSfere is widely successful because it brings together the ultimate combination of collaboration, productivity, security and compliance that is unmatched when compared to third-party consumer messaging services. We're extremely proud that NetSfere is among the top three enterprise messaging platforms, a clear indication that the well-established legacy platforms have been outpaced by enterprises' communication needs in the mobile era."

Ovum's report, "Secure Enterprise Messaging in the Age of the Chat App," proves a quick-growing need for reliable and secure enterprise messaging services. While most respondents use chat apps for one-to-one messaging for daily work tasks, about 60 percent also use it for group messaging, including one-to-one voice and video communications, and nearly 75 percent of respondents share confidential and non-confidential documents.

"Enterprises have a strict responsibility to ensure employees' communication is secure and confidential, especially those working in industries where communication records are required to be stored for auditing," said Pamela Clark-Dickson, Practice Leader of Ovum. "But our research shows that enterprises are allowing the use of consumer messaging apps that don't provide those vital security features."

The report finds that 65 percent of respondents are concerned about chat apps representing security loopholes and 50 percent are concerned about their inability to monitor communication. Despite enterprises' concerns over consumer messaging services, organizations have still allowed their usage. Sixty-seven percent of respondents allow employees to use consumer mobile messaging apps because they believe it is impossible to effectively block their usage.

In order to meet employees' demands for a simple-to-use, familiar messaging service, NetSfere delivers a similar look and functionality to mirror the popular consumer app experience, but adds the security and compliance features necessary for the workplace, including global cloud-based service availability, device-to-device encryption, location-based features and administrative controls. Built to meet a variety of industry-specific needs, NetSfere also offers regulatory compliances, such as SOX and HIPAA.

For more information about the study, please visit the website.

About Infinite Convergence Solutions
Infinite Convergence Solutions, Inc. provides next-generation messaging and mobility solutions to carriers and enterprises globally, including an Enterprise Messaging Services suite, secure messaging through its standalone service NetSfere (www.netsfere.com) and SMS, MMS and RCS solutions. The company's technology supports more than 400 million subscribers and over a trillion messages on an annual basis. Infinite Convergence Solutions is a subsidiary of Infinite Computer Solutions (BSE:533154) (NSE:INFINITE) with offices in the United States, Germany, India and Singapore.

About NetSfere
NetSfere is a secure enterprise messaging service from Infinite Convergence Solutions, Inc. NetSfere provides industry-leading security and message delivery capabilities, including global cloud-based service availability, device-to-device encryption, location-based features and administrative controls. The service leverages Infinite Convergence's experience in delivering mobility solutions to tier 1 mobile operators globally and technology that supports more than 400 million subscribers and over a trillion messages on an annual basis. NetSfere is also compliant with regulatory requirements, including the Health Insurance Portability and Accountability Act (HIPAA), Sarbanes-Oxley and others. For more information, visit www.netsfere.com.

About Ovum 
Ovum is a market-leading research and consulting firm focused on helping digital service providers and their technology partners thrive in the connected digital economy. Through its 150 analysts and consultants worldwide, it offers expert analysis and strategic insight across the IT, telecoms, and media industries. Founded in 1985, Ovum has one of the most experienced analyst teams in the industry and is a respected source of guidance for business leaders, CIOs, vendors, service providers, and regulators looking for comprehensive, accurate, and insightful market data, research, and consulting. With 23 offices across 6 continents, Ovum offers a truly global perspective on technology, communications, and media markets. It provides clients with insight, including workflow tools, forecasts, surveys, market assessments, technology audits, and opinion.

Ovum is part of the Business Intelligence Division of Informa PLC, a leading business intelligence, academic publishing, knowledge, and events group listed on the London Stock Exchange.

Contact
Christine Curtin
Uproar PR for Infinite Convergence 
ccurtin@uproarpr.com
(312) 878-4575 x242




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Infinite Convergence Solutions via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum